Setup

Hamilton Lane Incorporated is a $5.3B mid-cap alternative asset manager — private equity secondaries, direct equity, credit, infrastructure, private wealth. Their fiscal year ends March 31; the FY2026 10-K filed May 21 shows the business compounding at 29% FRE CAGR. The stock is down 44.5% from its 52-week high while the fundamentals improved.

What the Filing Says

FRE compounding. Fee Related Earnings grew 24.6% to $344.5M in FY2026. FRE margin expanded 520bps from 53.8% to 59.0% in a single year. Three-year FRE CAGR: 29% ($206.7M → $276.5M → $344.5M). Non-GAAP EPS $5.90 (+17.1%). OCF $424.9M (+41%). Cash $361M (+57% YoY). Debt declining ($293M → $281M). Dividend raised 11.1% to $0.60/quarter.

FRPR is the structural story. Fee Related Performance Revenues — evergreen fund high-water-mark incentive fees classified as recurring FRE — went $2.4M (FY2024) → $59.6M (FY2025) → $102.5M (FY2026). That's 17.5% of total revenues, +72% YoY. Four evergreen funds carry $14.3B combined NAV with inception returns of 16.0%, 25.2%, 12.6%, and 9.3%. FRPR compounds as NAVs cross new high-water marks — a mechanical function of NAV growth, not a periodic manager decision.

Evergreen driving fee-earning AUM. Fee-earning AUM grew $9.5B (+13.2%) to $81.5B. $6.6B of the $8.8B in specialized fund contributions came from evergreen. Blended fee rate stable at 71.6bps (FY2025: 71.4bps) — no compression. Evergreen mix shift is fee-rate accretive.

Secondary Fund VII formed. All fund vehicles confirmed in subsidiary list (VII-A LP Delaware, VII-B LP Delaware, VII-C Luxembourg SCSp RAIF, Aggregator SPV LLC, GP LLC). HLSF VI delivered 29.9% gross / 31.2% net IRR on $5.6B, 1.3x MOIC. First close for VII not yet disclosed. Secondary fundraising environment supportive: BX Strategic Partners raised $11B toward $22B+ in the current cycle; LP DPI pressure is active.

What the Market Thinks

At $90.32, HLNE trades at 15.3x non-GAAP EPS (market cap $5.27B, ≈58.4M diluted shares). Backing out the probability distribution implied by $90 against scenario prices ($165 bull / $128 base / $74 bear):

Market implies P(bull) ≈ 5%, P(base) ≈ 20%, P(bear) ≈ 75%.

Analyst consensus sits at $136 mean / $141 median across 7 analysts, 86% bullish — roughly 23-24x forward FRE. The implied 51% gap between street consensus and market price is the setup.

Why the Gap Exists

STEP divergence is the discriminator. StepStone Group (STEP) is the closest structural comp: same fiscal year end, same product set (secondaries + evergreen private wealth), similar AUM scale (≈$70B). STEP's FRE margin is 36-37%, flat year-over-year. HLNE's is 59%, +520bps. The 22 percentage point gap is product architecture: HLNE's evergreen funds generate HWM-based recurring performance fees that flow into FRE. STEP's comparable products do not have this structure at scale. A sector tailwind would lift STEP too; it hasn't.

FRPR misclassified in GAAP frameworks. The market is applying a static trailing multiple to an earnings stream that has structurally shifted composition. FRPR grew 42x in two years — $2.4M to $102.5M. Existing fund NAVs compound, cross new HWMs, crystallize fees. The re-labeling from "incentive fees" (lumpy, vintage-dependent) to recurring FRE hasn't yet moved the multiple. At 59% FRE margin, HLNE has converged to the BX/APO/KKR cluster (58-69%) despite being a fraction of their AUM scale. The size/liquidity discount is real, but the spread to peers at 15.3x vs 20-35x is wider than that discount warrants.

Insider validation, now below cost basis. Both co-CEOs (Juan Delgado-Moreira and Erik Hirsch) and the COO purchased open market on February 20 at approximately $107-108. Director Berkman purchased at $101 four days later. Four insiders, coordinated same week, writing checks with full Q3/Q4 FY2026 pipeline visibility. The 10-K filed May 21 confirms the business accelerated through their purchase date: FRE +24.6%, FRPR +72%, OCF +41%. Stock is now $90 — 16% below their cost basis with better fundamentals. (Form 4 primary verification pending — sourced from market data aggregator.)

The -44.5% wasn't fundamental. STEP fell -6.0%, BX fell -9.8% over the same 12 months vs SPY +30.2%. HLNE's -38.5pp underperformance versus STEP represents idio multiple compression, not business deterioration.

Risks

1. FRPR is equity-market-dependent. FRPR crystallizes only when evergreen NAVs exceed prior high-water marks. A 20%+ equity market correction depresses NAVs below HWMs, stopping crystallizations. FRE margin reverts to 54-56%. The four evergreen funds have inception returns of 9.3%-25.2%, providing buffer — but sustained correction erodes it.

2. Re-rating may not come on schedule. With 86% analyst consensus already bullish, the bull thesis is not a discovery. Without HLSF VII announcement or a sufficiently clean FRE earnings print, the stock could compound at the earnings rate (+17-25%) without the multiple lifting.

3. Form 4 unverified. The insider buying signal was sourced from a market data aggregator, not primary SEC Form 4 filings. If the purchases were grants or option exercises (codes A/M/F, not P), the signal collapses. This is the highest-impact outstanding verification.

4. Alt manager sector headwinds. STEP and BX have also underperformed SPY by 35-40pp. Sector re-rating requires institutional re-engagement with private equity and alt manager exposure — not HLNE-specific, and not within management's control.

Catalysts

• HLSF VII first close (unknown timing, P=72% by Dec 31, 2026): Watch 8-K Item 1.01. First close ≥$2B = +8-15% price response and meaningful fee-earning AUM step-up.
• Q1 FY2027 earnings (~August 2026): FRPR quarterly threshold ≥$20M confirms FY2027 trajectory toward $100M+. Below $18M in two consecutive quarters = stall signal.
• Form 4 verification (immediate): Manual EDGAR check, 30 minutes. Confirms or removes the highest-LR single evidence item. Thesis-gating before full sizing.
• 13F filings (August 2026): Institutional holdings for Q2 2026. New accumulation at $90 = independent buy-side confirmation.

What Would Change Our Mind

• Q1 FY2027 FRPR below $18M — if FRPR stalls before reaching $20M/quarter, the NAV-compounding thesis is not playing out at the rate the filing implies.
• Form 4 confirms grants, not open market — removes the coordinated insider signal entirely. The thesis survives on the FRE and FRPR evidence, but the highest-conviction single item disappears.
• STEP FY2026 10-K shows rapid FRPR catch-up — if STEP closes the FRE margin gap toward 45%+, the product architecture differentiation weakens and with it the multiple re-rating argument. (STEP annual 10-K for FY2026 not yet read — gap.)
• Any HLNE-specific 8-K with credit, operational, or governance issues — covenant breach, going concern, management departure → exit immediately regardless of price.

LR Signal: 1.5

Market underweighting the structural FRPR earnings shift and the convergent insider positioning. Evidence base is primarily Tier 1 (10-K, 0.95 credibility) with one high-LR item pending verification. The 86% analyst consensus caps the edge — this is not undercovered — but the stock's -44.5% return diverges sharply from both the filing and the consensus, and the STEP cross-ticker confirms the margin gap is structural, not sector beta.

Evidence